Asset
ELTANEXOR
Karyopharm Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02649790 | phase1_2 | completed | 2016-01-01 | 2024-08-31 | Karyopharm Therapeutics Inc | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications |
FDA applications (0)
This company has no applications containing this asset.